Hone's Branded GLP-1 Strategy

Hone’s GLP-1 expansion was a compliance choice as much as a growth choice. By sticking to branded, FDA approved drugs like liraglutide and Zepbound, Hone kept its weight loss business inside the standard telehealth and pharmacy workflow, where a doctor evaluates the patient, a prescription goes to a licensed pharmacy partner, and the patient receives a regulated product instead of a custom compounded copy that can trigger enforcement risk.

• This matters because the market got crowded with telehealth clinics selling compounded GLP-1s when branded supply was tight. As supply stabilized, the FDA ended semaglutide compounding discretion and then moved more aggressively against non approved compounded GLP-1 marketing in 2026, which raised the compliance cost of that model.
  2 fda 6 fda 7 fda
• Hone was already built around recurring medical management. Its testosterone business trained the company to handle ongoing labs, clinician follow up, dosing changes, and pharmacy fulfillment, which translates well to obesity drugs that also require screening, titration, side effect monitoring, and refill continuity.
  1 sacra 3 sacra 4 fda
• The tradeoff is economics. Branded drugs come with tighter supply and lower pricing flexibility than compounded copies, but they also make Hone look more like a durable care platform and less like a short term arbitrage business. That supports cross sell into women’s hormones, longevity therapies, and other long duration treatments.
  1 sacra 4 fda 5 fda

Going forward, GLP-1 telehealth should split into two lanes. One lane is regulated access to branded drugs through licensed partners. The other is shrinking under FDA pressure. Hone is positioned in the first lane, which should make its obesity offering more stable and make the broader platform easier to extend into additional chronic care categories.